Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy
European Journal of Cancer · 2026-06 · 242 · 116826
DOI: 10.1016/j.ejca.2026.116826 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Shiori Ishikawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Medical Oncology, Tohoku Univers…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Biliary Tract Neoplasms, Mutation, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Medical Oncology, Tohoku University Hospital, Sendai, Miyagi, Japan.
- Department of Medical Oncology, Tohoku University Hospital, Sendai, Miyagi, Japan.
- Clinical Research Data Center, Tohoku University Hospital, Sendai, Miyagi, Japan.
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Medical Oncology, Tohoku University Hospital, Sendai, Miyagi, Japan. Electronic address: kawakami_h@to…
Zitieren
APA
Ishikawa, S., Ouchi, K., Wakayama, S., Oyamada, S., Iwasaki, T., Numakura, R., Yoshida, Y., Taniguchi, S., Kasahara, Y., Komine, K., Saijo, K., Shirota, H., & Kawakami, H. (2026). Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. European Journal of Cancer, 242, 116826. https://doi.org/10.1016/j.ejca.2026.116826
Vancouver
Ishikawa S, Ouchi K, Wakayama S, Oyamada S, Iwasaki T, Numakura R, et al. Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. European Journal of Cancer. 2026;242:116826. doi:10.1016/j.ejca.2026.116826
BibTeX
@article{Ishikawa2026,
author = {Ishikawa, Shiori and Ouchi, Kota and Wakayama, Shonosuke and Oyamada, Shunsuke and Iwasaki, Tomoyuki and Numakura, Ryunosuke and Yoshida, Yuya and Taniguchi, Sakura and Kasahara, Yuki and Komine, Keigo and Saijo, Ken and Shirota, Hidekazu and Kawakami, Hisato},
title = {Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy},
journal = {European Journal of Cancer},
year = {2026},
volume = {242},
pages = {116826},
doi = {10.1016/j.ejca.2026.116826}
}
EUVIMED